We're exiting our position in a drug stock and initiating a stake in a more attractive rival

Sold 1,100 Bristol Myers Squibb shares at ~$58.94 and initiated 150 Johnson & Johnson shares at ~$237.65, leaving the trust with 0 BMY and 145 JNJ shares (~1% of the portfolio). The swap reflects a shift into J&J for stronger commercial execution: J&J reported ~$94B sales in 2025 (Innovative Medicines ~2/3), Oncology ~$25B in 2025 with a management target >$50B by 2030, and recent FDA approval of oral IL-23 inhibitor Icotyde; J&J also completed the Kenvue spin-off and plans a DePuy separation. Rationale: lock a ~3.5% gain in BMY after a missed Cobenfy trial and tariff worries, while initiating J&J with a $265 price target (~23x 2026 adj. EPS) and room to scale into the position.

Analysis

This swap is less about binary trial outcomes and more about tilting exposure from idiosyncratic, outcome-driven beta toward steady commercial optionality and corporate-structure optionality. A company with multiple organically growing, high-margin franchises and an active program of portfolio simplification will compound multiple expansion faster than a peer reliant on a small set of pipeline outcomes; that dynamic explains why capital should be redeployed even when the near-term chart looks similar.

Second-order winners include specialty CDMOs and oral small-molecule formulators: a successful oral IL-23 entrant changes payer formulary negotiations and shifts demand away from injectable biologics, compressing incumbent ASPs and increasing near-term manufacturing reallocation. Conversely, incumbent injectable specialists and biologics-focused manufacturers face margin pressure and slower volume growth trajectories if market share shifts accelerate.

Key near- and mid-term catalysts to watch are corporate-structure events (DePuy disposition/timing), payer uptake curves for new oral entrants, and a handful of phase III readouts that could reintroduce binary risk for the smaller pipeline-centric firm. Legal headlines will remain a volatility amplifier but are no longer the primary value driver — the path to further re-rating is now execution and capital-allocation clarity rather than headline settlements.

The tactical takeaway is: favor exposure to durable commercial growth and balance optionality on structural corporate actions with protection against trial/regulatory binary risk. Position sizing should reflect asymmetric upside from multiple re-rating over 24–36 months versus concentrated downside from single-event trial failures over the next 6–12 months.

Key Decisions for Investors

• Initiate a staged long in JNJ (start 1% portfolio, scale to 3–4% over 3–12 months): average-in on strength after upcoming earnings, target ~15–25% upside over 12–24 months from multiple expansion and separation optionality. Tactical stop at -12% from entry; add on confirmed DePuy separation path or material US payer uptake signals.
• Pair trade: long JNJ / short BMY (dollar-neutral, 1:1) for 6–12 months to harvest commercial-execution vs pipeline-binary spread — target 1,500–2,000 bps relative outperformance. Close pair if BMY posts positive phase III readouts or JNJ issues materially weaker guidance.
• Event-driven options play: buy a 9–12 month JNJ call spread ~10–20% OTM (cost-efficient capture of re-rating) while hedging with a small 9–12 month put spread on BMY to limit losses if trial risk re-emerges. Risk/reward: capped loss (premium) vs 2–4x upside on spread if market re-rates JNJ or BMY disappoints.
• Small opportunistic short on peers with high exposure to injectable biologics (e.g., ABBV or AMGN) sized 0.5–1% of portfolio as a hedge to a faster-than-expected oral IL-23 adoption curve; use puts if skew is favorable. Trim if incumbents report durable formulary wins or initial adoption lags expectations.